Partner Therapeutics has reported new findings from a post hoc analysis of the Phase II eNRGy trial (NCT02912949), indicating that continued treatment with zenocutuzumab beyond disease progression may provide sustained clinical benefit in patients with advanced neuregulin 1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC).
The data were presented at the 2026 International Association for the Study of Lung Cancer (IASLC) Targeted Therapies of Lung Cancer meeting.
NRG1+ NSCLC is a rare molecular subtype associated with limited response to non-targeted therapies and generally poor clinical outcomes, highlighting the need for effective targeted treatment strategies.
The analysis included 27 patients who continued zenocutuzumab treatment after radiographic progression and received at least three additional doses. Oligoprogression was observed in 81% of patients, while 19% experienced diffuse progression.
Median total exposure to zenocutuzumab increased to nearly 10 months, compared with approximately seven months prior to progression. Eight patients remained on treatment for more than six months beyond progression. One patient continued therapy for more than 23 months after progression, with treatment ongoing as of December 2025, while another patient remained on zenocutuzumab for nearly four years in total.
Additionally, 22% of patients continued treatment following local management of progressing lesions, including radiotherapy, gamma knife surgery and surgical resection. No patients discontinued treatment due to adverse events, and the safety profile remained consistent with prior reports.
NRG1 gene fusions are typically identified through tissue-based DNA and RNA next-generation sequencing.
Zenocutuzumab-zbco (BIZENGRI®) received accelerated approval from the U.S. Food and Drug Administration in December 2024 for adults with advanced unresectable or metastatic NSCLC and pancreatic adenocarcinoma harboring an NRG1 gene fusion whose disease progressed on or after prior systemic therapy.
The approval was based on overall response rate and duration of response, with continued approval contingent on confirmation of clinical benefit in ongoing trials.
Also Read